PMID- 31151406
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20200702
LR  - 20200702
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 10
IP  - 1
DP  - 2019 May 31
TI  - Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic 
      review and meta-analysis.
PG  - 150
LID - 10.1186/s13287-019-1258-1 [doi]
LID - 150
AB  - BACKGROUND: Heart failure (HF) is the end stage of most heart disease. 
      Mesenchymal stem cells (MSCs), with their specific biological effects, have been 
      applied in several clinical trials to evaluate the efficacy in HF therapy. We 
      performed this meta-analysis to review the clinical evidence of their therapeutic 
      effect on HF. METHODS: Three databases were searched. The outcomes of interest 
      were death, readmission, the 6-min walk test (6MWT), New York Heart Association 
      (NYHA) class and left ventricular ejection fraction (LVEF). The relative risk 
      (RR) and weighted mean difference (WMD) were calculated to evaluate the effects 
      of MSCs on HF compared to placebo. RESULTS: A total of nine studies were 
      included, involving 612 patients who underwent MSCs or placebo treatment. The 
      overall rate of death showed a trend of reduction of 36% (RR [CI] = 0.64 [0.35, 
      1.16], p = 0.143) in the MSC treatment group. The incidence of readmission was 
      reduced by 34% (RR [CI] = 0.66 [0.51, 0.85], p = 0.001). The patients in the MSC 
      treatment group realised an average of 40.44 m (WMD [95% CI] = 40.44 m [19.07, 
      61.82], p < 0.0001) improvement in 6MWT. The NYHA class was reduced obviously in 
      the MSC group (WMD [95% CI] = - 0.42 [- 0.64, - 0.20], p < 0.0001). The changes 
      of LVEF from baseline were significantly more than 5.25% (WMD [95% CI] = 5.25 
      [3.58, 6.92], p < 0.0001) in the MSCs group, unlike in the placebo group. 
      CONCLUSIONS: Our results suggested that MSC treatment is an effective therapy for 
      HF by improving the prognosis and exercise capacity. SCs derived from allosomes 
      have superior therapeutic effects, and intracoronary injection is the optimum MSC 
      delivery approach. Short-term cryopreservation is feasible in MSCs storage or 
      transport.
FAU - Fan, Mengkang
AU  - Fan M
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
FAU - Huang, Yin
AU  - Huang Y
AD  - Department of Geriatric Medicine, Affiliated Hospital of Nantong University, 
      Nantong, Jiangsu, China.
FAU - Chen, Zhangwei
AU  - Chen Z
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
FAU - Xia, Yan
AU  - Xia Y
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
FAU - Chen, Ao
AU  - Chen A
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
FAU - Lu, Danbo
AU  - Lu D
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
FAU - Wu, Yuan
AU  - Wu Y
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
FAU - Zhang, Ning
AU  - Zhang N
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
FAU - Qian, Juying
AU  - Qian J
AD  - Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, 
      Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. 
      qian.juying@zs-hospital.sh.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190531
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
EIN - Stem Cell Res Ther. 2019 Jul 15;10(1):206. PMID: 31307531
PMC - PMC6544951
OTO - NOTNLM
OT  - Heart failure
OT  - Mesenchymal stem cells
OT  - Stem cell transplantation
COIS- The authors declare that they have no competing interests.
EDAT- 2019/06/04 06:00
MHDA- 2019/06/04 06:01
PMCR- 2019/05/31
CRDT- 2019/06/02 06:00
PHST- 2019/04/08 00:00 [received]
PHST- 2019/05/08 00:00 [accepted]
PHST- 2019/05/07 00:00 [revised]
PHST- 2019/06/02 06:00 [entrez]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2019/06/04 06:01 [medline]
PHST- 2019/05/31 00:00 [pmc-release]
AID - 10.1186/s13287-019-1258-1 [pii]
AID - 1258 [pii]
AID - 10.1186/s13287-019-1258-1 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2019 May 31;10(1):150. doi: 10.1186/s13287-019-1258-1.